Massive Wave Research Healthcare has partnered with a biopharma organisation to conduct market research that will help us better understand the paediatric sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT) patient journey.
Given our shared objectives to empower patients and improve the quality of care they receive, we are inviting the following groups of specialists who actively manage paediatric SCD and TDT patients to participate in this upcoming study:
As a token of appreciation for their time, each successful respondent will receive up to £200 upon completion of the study (depending on their specialty).